

## **Nektar & Rigel - Expert Call on RA Drugs**

**Thursday, February 26th**

**11:00am est**



**Featured Expert :** **Dr. Theodore Fields, M.D. FACP**

Clinical Director, Gosden Robinson Early Arthritis Center

Hospital for Special Surgery

**Hosted by:** **WJB Capital Group**

**Compound:** R788 from Rigel (RIGL)

Cimzia from Nektar (NKTR)

**Indication:** Rheumatoid Arthritis (RA)

**Status:** Phase 11b (TASKi-2 and 3) trial data is expected in early Q3/Bla filed

**Expert Bio:** Dr. Fields is the Clinical Director, Gosden Robinson Early Arthritis Center at the Hospital for Special Surgery as well as an Associate Professor of Clinical Medicine, Weill Medical College of Cornell University. He is a member of the American College of Physicians (FACP), a Fellow of the American College of Rheumatology, and a Fellow at the Hospital for Special Surgery. In turn, he serves on the Medical Board and the Physician-Hospital Organization (PHO), and is on the Board of Directors at the Hospital for Special Surgery.

Dr. Fields graduated from the State University of New York Medical Center at Brooklyn in 1976. He completed his residency in internal medicine at the Nassau County Medical Center. Then, he did rheumatology fellowship at the State University of New York at Stony Brook. Dr. Fields has significant expertise in gout, rheumatoid arthritis and osteoarthritis.

**Discussion Topic:** **Rigel's R788**, an oral disease modifying anti-rheumatic drug (DMARD), is part of a new class of drugs that blocks an inflammatory protein called syk kinase. Rigel expects results from the two Phase 2b clinical trials of R788, TASKi2 and TASKi3, to be available in July and August 2009, respectively. Rigel is exploring the use of R788 in a range of clinical settings in addition to RA including ITP, b-cell lymphoma, and SLE.

**Nektar's Cimzia** is a monoclonal antibody directed TNF-alpha. It is an approved agent for Moderate To Severe Crohn's Disease. Cimzia is being evaluated in RA at a dosing of once every two weeks and once every four weeks, via subcutaneous administration.

With our expert, Dr. Theodore Fields, we will discuss the two agents' current clinical and safety profile, the potential regulatory pathways, as well as the key clinical, safety and commercial drivers and challenges within the RA setting.

\* Dr. Fields is a leading expert on Rheumatoid Arthritis and rarely speaks to the street. He will provide insight after the release of quarterly numbers and talk about upcoming catalysts.

**[Click HERE to RSVP](#)**